Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During "J.P. Morgan Week 2025"
Monday, 6th January at 8:30 am Management to meet with investors and potential partners during Biotech Showcase 2025
Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced Joseph Tucker, Ph.D., CEO, will participate in a panel discussion and present at the Sachs Associates 8th Annual Neuroscience Innovation Forum on January 12, 2025. Additionally, Enveric will attend Biotech Showcase 2025 from January 13-15, 2025. Both conferences are being held in San Francisco during "J.P. Morgan Week 2025."
During the events, members of Enveric's management team will conduct one-on-one meetings with registered investors and potential partners, showcasing the company's business and clinical development strategy, recent corporate achievements, and anticipated milestones.
Details are as follows:
Event:
Sachs Associates 8th Annual Neuroscience Innovation Forum
Panel:
Future of Psychedelics - January 12, 2025, at 2:20 p.m., PDT
Presentation:
4:05 p.m., PDT, January 12, 2025 - Track E - Room Heritage